More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Lovastatin [75330-75-5]
Chemical Structure
Chemical Structure
Chemical Structure

Lovastatin [75330-75-5]

Research Use Only
AG-CN2-0051
AdipoGen Life Sciences
CAS Number75330-75-5
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight404.6
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Lovastatin [75330-75-5]
  • Delivery Days Customer
    10
  • CAS Number
    75330-75-5
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Warning
  • Molecular Formula
    C24H36O5
  • Molecular Weight
    404.6
  • Scientific Description
    Chemical. CAS: 75330-75-5. Formula: C24H36O5. MW: 404.6. Synthetic. Statin compound. Potent competitive HMG-CoA reductase inhibitor. Anti-hypercholesterolemic agent. Cholesterol/isoprenoid biosynthesis inhibitor. Blocks the production of mevalonate, a critical compound in the production of cholesterol and isoprenoids. Inhibits the isoprenylation of Ras and Rho family GTPases. Causes cell cycle arrest in G1 and G2/M phases through modulation of proteasome in cancer cell lines. Smooth muscle cell proliferation inhibitor. Apoptosis inducer. Anticancer compound. Anti-adhesive, immunomodulatory and anti-inflammatory compound. Stimulates bone formation. Increases cellular resistance to anticancer agents such as doxorubicin and etoposide (Prod. No. AG-CR1-3572 http://www.adipogen.com/ag-cr1-3572/etoposide.html ). Suppresses ICAM-1-LFA-1 interactions, which blocks virus replication and infection. Anti-hypertensive agent. Suppresses TNF-induced NF-kappaB activation. Modulates key cell signaling pathways, like Ras, MAPK and EGFR (modest). - Statin compound. Potent competitive HMG-CoA reductase inhibitor. Anti-hypercholesterolemic agent. Cholesterol/isoprenoid biosynthesis inhibitor. Blocks the production of mevalonate, a critical compound in the production of cholesterol and isoprenoids. Inhibits the isoprenylation of Ras and Rho family GTPases . Anticancer compound that causes cell cycle arrest in G1 and G2/M phases through modulation of proteasome in cancer cell lines. SKP2 E3 ligase inhibitor. Decreases the expression of Skp2 and results in the inhibition of Skp2-mediated ubiquitination and degradation of p27 and p21, leading to cell cycle arrest and apoptosis. Smooth muscle cell proliferation inhibitor. Anti-adhesive, immunomodulatory and anti-inflammatory compound that stimulates bone formation. Suppresses TNF-induced NF-kappaB activation. Increases cellular resistance to anticancer agents such as doxorubicin and etoposide (Prod. No. AG-CR1-3572 http://www.adipogen.com/ag-cr1-3572/etoposide.html ). Suppresses ICAM-1-LFA-1 interactions, which blocks virus replication and infection. Anti-hypertensive agent. Modulates key cell signaling pathways, like Ras, MAPK and EGFR (modest). Lovastatin-treated neurons exhibit shortened neurite outgrowth.
  • SMILES
    [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent: A.W. Alberts, et al.; PNAS 77, 3957 (1980)
  • All ras proteins are polyisoprenylated but only some are palmitoylated: J.F. Hancock, et al.; Cell 57, 1167 (1989)
  • Cell cycle-specific effects of lovastatin: M. Jakobisiak, et al.; PNAS 88, 3628 (1991)
  • Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types: P. Negre-Aminou, et al.; Biochim. Biophys. Acta 1345, 259 (1997)
  • Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis: W.H. Park, et al.; Anticancer Res. 19, 3133 (1999)
  • Statins as a newly recognized type of immunomodulator: B. Kwak, et al.; Nat. Med. 6, 1399 (2000)
  • Lovastatin and simvastatin are modulators of the proteasome: C. Wojcik, et al.; Int. J. Biochem. Cell Biol. 32, 957 (2000)
  • Statins and bone formation: I.R. Garrett, et al.; Curr. Pharm. Des. 7, 715 (2001)
  • The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide: R.V. Bardeleben, et al.; Int. J. Mol. Med. 10, 473 (2002)
  • HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection: L.J. Raggatt & N.C. Partridge; Drugs 62, 2185 (2002) (Review)